S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
Log in
NASDAQ:EYPT

Eyepoint Pharmaceuticals Stock Forecast, Price & News

$0.52
-0.02 (-3.43 %)
(As of 09/30/2020 04:58 PM ET)
Add
Compare
Today's Range
$0.50
Now: $0.52
$0.55
50-Day Range
$0.48
MA: $0.56
$0.68
52-Week Range
$0.46
Now: $0.52
$2.69
Volume687,997 shs
Average Volume1.28 million shs
Market Capitalization$64.87 million
P/E RatioN/A
Dividend YieldN/A
Beta1.13
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. The company also offers DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. In addition, it develops YUTIQ shorter-acting uveitis for the treatment of NIPU; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Further, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, and Ocumension Therapeutics. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Read More
Eyepoint Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.30 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYPT
CUSIPN/A
Phone617-926-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.36 million
Book Value$0.08 per share

Profitability

Net Income$-56,790,000.00
Net Margins-229.34%

Miscellaneous

Employees55
Market Cap$64.87 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$0.52
-0.02 (-3.43 %)
(As of 09/30/2020 04:58 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EYPT News and Ratings via Email

Sign-up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions

How has Eyepoint Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Eyepoint Pharmaceuticals' stock was trading at $1.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EYPT shares have decreased by 50.7% and is now trading at $0.5181.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Eyepoint Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Eyepoint Pharmaceuticals
.

When is Eyepoint Pharmaceuticals' next earnings date?

Eyepoint Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Eyepoint Pharmaceuticals
.

How were Eyepoint Pharmaceuticals' earnings last quarter?

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The business had revenue of $4.12 million for the quarter, compared to analysts' expectations of $2.81 million. Eyepoint Pharmaceuticals had a negative net margin of 229.34% and a negative return on equity of 452.45%.
View Eyepoint Pharmaceuticals' earnings history
.

What price target have analysts set for EYPT?

3 equities research analysts have issued 12-month price targets for Eyepoint Pharmaceuticals' shares. Their forecasts range from $1.00 to $5.00. On average, they expect Eyepoint Pharmaceuticals' share price to reach $3.50 in the next twelve months. This suggests a possible upside of 575.5% from the stock's current price.
View analysts' price targets for Eyepoint Pharmaceuticals
.

Are investors shorting Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 2,210,000 shares, an increase of 14.5% from the August 15th total of 1,930,000 shares. Based on an average trading volume of 2,480,000 shares, the days-to-cover ratio is currently 0.9 days. Currently, 2.7% of the company's shares are sold short.
View Eyepoint Pharmaceuticals' Short Interest
.

Who are some of Eyepoint Pharmaceuticals' key competitors?

What other stocks do shareholders of Eyepoint Pharmaceuticals own?

Who are Eyepoint Pharmaceuticals' key executives?

Eyepoint Pharmaceuticals' management team includes the following people:
  • Ms. Nancy S. Lurker, Pres, CEO & Director (Age 62)
  • Mr. Leonard S. Ross, VP of Fin. & Chief Accounting Officer (Age 69)
  • Dr. Dario A. Paggiarino, VP & Chief Medical Officer (Age 62)
  • Mr. David J. Price, Chief Financial Officer (Age 56)
  • Mr. Marty Nazzaro, Sr. VP of Operations

What is Eyepoint Pharmaceuticals' stock symbol?

Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

How do I buy shares of Eyepoint Pharmaceuticals?

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eyepoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $0.52.

How big of a company is Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals has a market capitalization of $64.87 million and generates $20.36 million in revenue each year. The company earns $-56,790,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Eyepoint Pharmaceuticals employs 55 workers across the globe.

What is Eyepoint Pharmaceuticals' official website?

The official website for Eyepoint Pharmaceuticals is eyepointpharma.com.

How can I contact Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.